Global Pet Vaccine Market Size, Share, Opportunities, And Trends By Animals Type (Canine, Feline, Others), By Vaccination (Canine Family (Core Vaccines, Non-Core Vaccines), Feline Family (Core Vaccines, Non-Core Vaccines), Others), By Mode Of Administration (Injectable Vaccines, Intranasal Vaccines), And By Geography - Forecasts From 2023 To 2028

The global pet vaccine market is predicted to grow at a CAGR of 6.45%, from US$1,172.217 million in 2021 to US$1,816.076 million by 2028.

The global pet vaccine market is anticipated to grow steadily throughout the forecast period. Regular vaccination is an important part of responsible pet ownership. Maintaining the pet’s immunity to diseases is important to community health in general. The growing adoption rate of pets and growing community awareness regarding pet health has been significantly driving the demand for the global pet vaccine market.

Growth drivers of the global pet vaccine market.

The market is expanding because of rising zoonotic illnesses, product releases, and the increasing companion animal population. Additionally, a result of technological developments in the development of pet health vaccines, positive government initiatives, rising public awareness, and growing expenditure on R&D of animal vaccines are further leading to market growth.

Increasing prevalence of diseases in companion animals.

Animal diseases are becoming more prevalent, and people are becoming increasingly aware of them. Therefore, the market for pet vaccinations is anticipated to grow because of rising instances of animal diseases, animal welfare campaigns, and supportive government efforts. Further, due to the increased adoption of companion animals for social interaction and a healthy lifestyle because of rising public awareness, there has been an increase in pet ownership. For instance, according to the Industrial Association of Pet Care Producers (IVH) and the German Pet Trade and Industry Association (ZZF), 47% of German households had pets in 2021. Additionally, according to FEDIAF, in 2022, 90 million European homes (46%) owned pets, supporting the trend toward increased pet ownership in Europe.

The effectiveness of pet vaccinations to further accelerate the market.

According to the American Pet Products Association, the U.S. pet industry expenditure increased from US$123.6 billion in 2021 to US$136.8 billion in 2022. Moreover, as vaccinations are one of the safest and most economical ways to avoid infectious diseases, it has long been a focus of canine therapy. Dog adoption is increasing, and industry players are launching new products, driving this market segment. For instance, according to the results of the 2020 Pet Population Survey released in February 2021 by the Canadian Animal Health Institute (CAHI), the number of dogs in Canada increased from 7.6 million to 7.7 million.

The canine vaccine market is anticipated to grow substantially.

The most common canine diseases are rabies, Lyme disease, heartworm, canine parvovirus, and leptospires. According to the World Health Organization, around 99% of rabies infections are transmitted by dogs which can be prevented by vaccines. Nearly US$8.6 billion annually is spent globally for rabies, and 29 million people get post-exposure prophylaxis (PEP) annually as an emergency response to rabies exposure. Rabies is endemic in 9 countries of the Southeast Asia region, with Bangladesh bearing 45% of global rabies cases. According to the Global Alliance for Rabies Control, it causes 933 human deaths annually in Bangladesh annually.

According to UNICEF, demand from low and middle-income countries for rabies vaccines exceeds 1 million doses, and the commitment of UNICEF to countries makes the supply of vaccines available at a lower price. Therefore, the rising cases of rabies (vaccine-preventable disease) are expected to bolster the canine pet vaccine market growth.

The effectiveness of injectable vaccines.

Injectable vaccines are the ones that are efficiently designed to protect against various infectious diseases that can affect pets, such as dogs and cats. Injectable vaccines are a common and widely used form of vaccination in veterinary medicine. They are typically administered by a veterinarian or trained veterinary professional. The vaccine is injected either subcutaneously (under the skin) or intramuscularly (into the muscle), depending on the specific vaccine and the animal being vaccinated.

Injectable pet vaccines work by introducing a small, harmless portion of a pathogen or a modified version into the animal's body. This stimulates the pet's immune system to recognize the pathogen and develop a protective response. If the pet is later exposed to the disease-causing pathogen, its immune system is better prepared to fight it off, reducing the likelihood and severity of infection.

The United States is the dominant market in the North American region. 

The country’s surge in pet ownership is particularly notable among millennial households, characterized by smaller family sizes and delayed parenthood. This trend of pet ownership has been associated with various positive impacts on human health, including improved cardiovascular health, reduced depression and anxiety, and overall well-being. The empirical evidence suggests that owning pets can lead to favourable health outcomes for individuals. This phenomenon highlights the multifaceted benefits of pet ownership in terms of companionship and promoting human health and wellness. The ownership of pets in the United States exhibited a slight increase from 68 percent in 2016 to 70 percent as of 2022, indicating a prevalent presence of pets in most households during this period.

The data indicating a population of 85 million dogs and 65 million cats in the United States in 2022 reflects the significant presence of pets in the country. This substantial pet population provides a considerable market for pet vaccines. With many dogs and cats requiring regular vaccinations to maintain their health and prevent the spread of diseases, the growth of the pet vaccine market is expected to be driven by the necessity of meeting the healthcare needs of these pets in the USA.

Market Developments:

• In July 2022, the University of Wisconsin School of Veterinary Medicine and two other institutions started a clinical trial for vaccination against canine cancer study to develop a vaccine that would prevent dogs from developing cancer in the first place.
• In September 2022, the Kerala Government initiated a month-long vaccination drive for all stray dogs to deal with the stray dog menace in the state. This initiative and key developments create a demand for canine vaccines, thereby boosting the canine pet vaccine market size.
• In 2020. Elanco, a global animal health company, completed the acquisition of Bayer Animal Health. This merger expanded Elanco's portfolio of injectable vaccines for pets, including for companion animals such as dogs and cats.

Global Pet Vaccine Market Scope:

 

Report Metric	Details
Market Size Value in 2021	US$1,172.217 million
Market Size Value in 2028	US$1,816.076 million
Growth Rate	CAGR of 6.45% from 2021 to 2028
Base Year	2021
Forecast Period	2023 – 2028
Forecast Unit (Value)	USD Million
Segments Covered	Animal Type, Vaccination, Administration, and Geography
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered	Bayer AG, Elanco US Inc., Merck Sharp & Dohme Corp, Merial Inc., Virbac, Zoetis, Phibro Animal Health Corporation, Boehringer Ingelheim GmbH, Tianjin Ringpu Bio-Technology Co., Ltd, Vetoquinol
Customization Scope	Free report customization with purchase

 

Market Segmentation:

• By Animal Type
  • Canine
  • Feline
  • Equine
• By Vaccination
  • Canine Family
    • Core Vaccines
    • Non-Core Vaccines
  • Feline Family
    • Core Vaccines
    • Non-Core Vaccines
  • Others
• By Administration
  • Injectable Vaccines
  • Intranasal Vaccines
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Taiwan
    • Thailand
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumption

1.7. Base, and Forecast Year Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GLOBAL PET VACCINE MARKET, BY ANIMAL TYPE

5.1. Introduction

5.2. Canine

5.3. Feline

5.4. Equine

6. GLOBAL PET VACCINE MARKET, BY VACCINATION

6.1. Introduction

6.2. Canine Family

6.2.1. Core Vaccines

6.2.2. Non-Core Vaccines

6.3. Feline Family

6.3.1. Core Vaccines

6.3.2. Non-Core Vaccines

6.4. Others

7. GLOBAL PET VACCINE MARKET, BY MODE OF ADMINISTRATION

7.1. Introduction

7.2. Injectable Vaccines

7.3. Intranasal Vaccines

8. GLOBAL PET VACCINE MARKET, BY GEOGRAPHY

8.1. Introduction 

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Taiwan

8.6.7. Thailand

8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Bayer AG

10.2. Elanco US Inc. 

10.3. Merck Sharp & Dohme Corp

10.4. Merial Inc.

10.5. Virbac

10.6. Zoetis

10.7. Phibro Animal Health Corporation

10.8. Boehringer Ingelheim GmbH

10.9. Tianjin Ringpu Bio-Technology Co., Ltd

10.10. Vetoquinol

Bayer AG

Elanco US Inc.

Merck Sharp & Dohme Corp

Merial Inc.

Virbac

Zoetis

Phibro Animal Health Corporation

Boehringer Ingelheim GmbH

Tianjin Ringpu Bio-Technology Co., Ltd

Vetoquinol